A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm

Bourne, S. P.; Patel, Kalpana; Walsh, Frank S.; Popham, C; Coakham, Hugh B.; Kemshead, J. T.

doi:10.1007/bf00146871

Cited by 52 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies were purified from tissue culture supernatant by protein A-Sepharose chromatography. Two anti-NCAMs, ERIC-1, an IgGI (Bourne et al, 1991), and an IgG2a antibody (both supplied by J. Kemshead, ICRF, Frenchay Hospital, Bristol, UK) were used as positive controls. A locally produced IgGI antibody, QS4120, an anti-human CD4 (P. Beverley, personal communication) was used as a negative control antibody.…”

Section: Methodsmentioning

confidence: 99%

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

Olabiran

Ledermann²,

Marston³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

Summary Spheroids of a small-cell lung cancer (SCLC) cell line POC were used to evaluate the uptake and penetration of two antibodies recognising different SCLC antigens. Spheroids approximately 300-400 gm in diameter were incubated with 1 jig ml-"25I-labelled NY.3DI 1, an antibody which reacts with the cluster I group antigen (neural cell adhesion molecule; NCAM) and ['25I]SWAI 1, which binds to the cluster w4 antigen. The rate of uptake of both antibodies was similar; an initially rapid phase was seen during the first 8 h and maximum uptake occurred by 24 h. This increased to about 100 txm after 4 h incubation with I or 100 fig ml-' SWAI 1. The results with I lg mlh' NY.3D1 were similar, but in the presence of 100 jg ml-' NY.3DI I penetration into the spheroid was deep and diffuse. These results demonstrate a major concentration-dependent difference in the uptake and penetration of cluster I and cluster w4 antibodies in this spheroid model and they have implications for the selection of antibodies for targeted therapy of SCLC.

show abstract

Section: Methodsmentioning

confidence: 99%

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

Olabiran

Ledermann²,

Marston³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Forty-eight h after transfection, cell lysates were made from the transfected cells and incubated with a mouse anti-human N-CAM monoclonal antibody (ERIC-1, Santa Cruz Biotechnology) (27), followed by protein G-agarose (Pierce). After solubilization, the immunoprecipitates were separated by SDS-polyacrylamide (5%) gel electrophoresis and transferred onto nitrocellulose membrane.…”

Section: Western Blot Analysis Of N-cam Expressing the Hnk-1 Carbohydmentioning

confidence: 99%

Expression Cloning of a Human Sulfotransferase That Directs the Synthesis of the HNK-1 Glycan on the Neural Cell Adhesion Molecule and Glycolipids

Ong¹,

Yeh

Ding

et al. 1998

Journal of Biological Chemistry

107

View full text Add to dashboard Cite

The HNK-1 carbohydrate is expressed on various adhesion molecules in the nervous system and is suggested to play a role in cell-cell and cell-substratum interactions. Here we describe the isolation and functional expression of a cDNA encoding a human sulfotransferase that synthesizes the HNK-1 carbohydrate epitope. A mutant Chinese hamster ovary cell line, Lec2, which stably expresses human neural cell adhesion molecule (N-CAM) (Lec2-NCAM), was first established. Lec2-NCAM was co-transfected with a human fetal brain cDNA library, a cDNA encoding the rat glucuronyltransferase that forms a precursor of the HNK-1 carbohydrate, and a vector encoding the polyoma large T antigen. The transfected Lec2-NCAM cells expressing the HNK-1 glycan were enriched by fluorescence-activated cell sorting. Sibling selection of recovered plasmids resulted in a cDNA encoding a sulfotransferase, HNK-1ST, that directs the expression of the HNK-1 carbohydrate epitope on the cell surface. The deduced amino acid sequence indicates that the enzyme is a type II membrane protein. Sequence analysis revealed that there is a short amino acid sequence in the presumed catalytic domain, which is highly homologous to the corresponding sequence in other Golgi-associated sulfotransferases so far cloned. The amount of HNK-1ST transcript is high in fetal brain compared with fetal lung, kidney, and liver. Expression of HNK-1ST resulted in the formation of the HNK-1 epitope on N-CAM and a soluble chimeric form of HNK-1ST was shown to add a sulfate group to a precursor, GlcA␤133Gal␤134GlcNAc␤13 R, forming sulfo33GlcA␤133Gal␤134GlcNAc␤13 R. The results combined together indicate that the cloned HNK-1ST directs the synthesis of the HNK-1 carbohydrate epitope on both glycoproteins and glycolipids in the nervous tissues.

show abstract

“…Our approach can therefore be regarded as a 'liquid phase brachytherapy'. In this study, we have used a MoAb that recognises NCAM expressed on all gliomas studied (n>50) as well as both normal neural and glial cells (Bourne et al, 1991). Binding is predominantly restricted to tumour, because access to normal brain is limited.…”

Section: Discussionmentioning

confidence: 99%

“…The MoAb used in these studies, ERIC-1, recognises NCAM expressed on all gliomas examined (n = > 50), as well as both normal neural and astrocytic elements within the brain (Bourne et al, 1991). Radioimmunoscintigraphy with tracer amounts of "3'I-ERIC-1 (37 MBq) showed that the conjugate predominantly remained within the tumour cyst.…”

Section: Immunocytochemistry and Immunoscintigraphymentioning

confidence: 97%

Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry

Papanastassiou

Pizer²,

Coakham³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

show abstract

A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumours arising from the neuroectoderm

Cited by 52 publications

References 26 publications

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

Expression Cloning of a Human Sulfotransferase That Directs the Synthesis of the HNK-1 Glycan on the Neural Cell Adhesion Molecule and Glycolipids

Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry

Contact Info

Product

Resources

About